Green Alpha Advisors LLC Takes Position in Twist Bioscience Corporation $TWST

Green Alpha Advisors LLC purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,178 shares of the company’s stock, valued at approximately $533,000.

A number of other institutional investors have also made changes to their positions in the stock. BlackRock Inc. acquired a new position in Twist Bioscience in the second quarter valued at about $600,191,000. William Blair Investment Management LLC grew its position in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after buying an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. increased its stake in shares of Twist Bioscience by 31.7% in the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter. Millennium Management LLC increased its stake in shares of Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after acquiring an additional 1,080,722 shares during the last quarter. Finally, ARK Investment Management LLC raised its position in shares of Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after acquiring an additional 832,687 shares during the period.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the transaction, the insider owned 105,141 shares in the company, valued at $9,436,404.75. This represents a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Emily M. Leproust sold 113,318 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.16, for a total transaction of $14,182,880.88. Following the sale, the chief executive officer directly owned 818,938 shares of the company’s stock, valued at $102,498,280.08. This represents a 12.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 151,529 shares of company stock worth $17,708,772. Corporate insiders own 3.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TWST. Barclays lifted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Piper Sandler increased their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a research report on Thursday, July 16th. Finally, TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.30.

Twist Bioscience Trading Up 6.8%

NASDAQ:TWST opened at $145.59 on Friday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $145.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a market capitalization of $9.13 billion, a PE ratio of -65.58 and a beta of 2.14. The business’s 50-day simple moving average is $100.69 and its 200-day simple moving average is $70.33.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the prior year, the firm posted $0.33 earnings per share. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. Sell-side analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.